Navigation Links
Boston Scientific Launches New Coronary Imaging Catheter

NATICK, Mass., March 19 /PRNewswire-FirstCall/ -- Boston Scientific Corporation (NYSE: BSX) today announced the launch of its iCross(TM) Coronary Imaging Catheter, a product designed to improve the deliverability of the Company's market-leading intravascular ultrasound (IVUS) technology, the iLab(R) Ultrasound Imaging System. IVUS technology enables physicians to see detailed images inside the heart and coronary arteries. The Company said the iCross Catheter would be available immediately in the United States.

"Boston Scientific's iCross Coronary Imaging Catheter is a powerful tool for visualizing coronary intravascular pathology, especially in patients with complex coronary artery disease," said Augusto Pichard, M.D., Director, Cardiac Catheterization Lab, Washington Hospital Center. "The combination of the iCross' outstanding image quality and excellent deliverability should help physicians better identify lesion characteristics."

"This latest advance builds on the success of our existing Atlantis(R) SR Pro Catheter," said Hank Kucheman, Senior Vice President and Group President, Cardiovascular for Boston Scientific. "We expect that the improvements iCross offers to physicians and their patients will help further solidify our leadership in intravascular ultrasound."

The iCross Catheter features a Bioslide(R) Hydrophilic Coating that has been shown in bench tests to provide a 28 percent improvement in pushability in challenging anatomy(1).

Boston Scientific is a worldwide developer, manufacturer and marketer of medical devices whose products are used in a broad range of interventional medical specialties. For more information, please visit:

Cautionary Statement Regarding Forward-Looking Statements

This press release contains forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934. Forward-looking statements may be identified by words like "anticipate," "expect," "project," "believe," "plan," "estimate," "intend" and similar words. These forward-looking statements are based on our beliefs, assumptions and estimates using information available to us at the time and are not intended to be guarantees of future events or performance. These forward-looking statements include, among other things, statements regarding new product development and performance, regulatory approvals, alternative technologies and our growth strategy. If our underlying assumptions turn out to be incorrect, or if certain risks or uncertainties materialize, actual results could vary materially from the expectations and projections expressed or implied by our forward-looking statements. These factors, in some cases, have affected and in the future (together with other factors) could affect our ability to implement our business strategy and may cause actual results to differ materially from those contemplated by the statements expressed in this press release. As a result, readers are cautioned not to place undue reliance on any of our forward-looking statements.

Factors that may cause such differences include, among other things: future economic, competitive, reimbursement and regulatory conditions; new product introductions; demographic trends; intellectual property; litigation; financial market conditions; and, future business decisions made by us and our competitors. All of these factors are difficult or impossible to predict accurately and many of them are beyond our control. For a further list and description of these and other important risks and uncertainties that may affect our future operations, see Part I, Item 1A- Risk Factors in our most recent Annual Report on Form 10-K filed with the Securities and Exchange Commission, which we may update in Part II, Item 1A - Risk Factors in Quarterly Reports on Form 10-Q we have filed or will file thereafter. We disclaim any intention or obligation to publicly update or revise any forward-looking statements to reflect any change in our expectations or in events, conditions, or circumstances on which those expectations may be based, or that may affect the likelihood that actual results will differ from those contained in the forward-looking statements. This cautionary statement is applicable to all forward-looking statements contained in this document.

(1) Pushability is the amount of force required to push a catheter to a specific depth in the anatomy. Testing completed by Boston Scientific Corp. Data on file. Bench test results may not necessarily be indicative of clinical performance. Twenty-eight percent improvement as compared to Boston Scientific's Atlantis SR Pro catheter.

    CONTACTS:  Paul Donovan
               508-650-8541 (office)
               508-667-5165 (mobile)
               Media Relations
               Boston Scientific Corporation

               Larry Neumann
               508-650-8696 (office)
               Investor Relations
               Boston Scientific Corporation

SOURCE Boston Scientific Corporation
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Moodys Raises Boston Scientifics Rating Outlook to Stable
2. BG Medicine Signs Collaborative Research Agreement with the National Heart, Lung and Blood Institute (NHLBI), and Boston University
3. Nektar Therapeutics President and CEO, Howard W. Robin, to Present at the 29th Annual Cowen and Company Healthcare Conference in Boston
4. Boston LASIK Eye Surgery Expert Dr. Peter Rapoza Joins Select Group of Doctors in Trusted LASIK Surgeons Directory
5. Boston Scientific Resolves Outstanding Litigation Matter, Finalizes Goodwill Impairment Charge
6. Boston Scientific Announces Japanese Approval for TAXUS(R) Liberte(R) Drug-Eluting Stent System
7. Biotechnology Veteran Michael Webb Joins Boston-based Investment Bank as Senior Advisor
8. Boston Scientific Acquires Labcoat Limited
9. FDA Approves Boston Scientifics Express(R) SD Renal Stent System
10. Kendle to Present at the 2008 Raymond James Boston Fall Investors Conference
11. Boston Scientific to Participate in Piper Jaffray Health Care Conference
Post Your Comments:
(Date:10/13/2015)... -- Amgen (NASDAQ: AMGN ) and LabCentral announced today ... 2015 selection for Golden Ticket winners, which supply each ... innovative, shared laboratory space designed as a launchpad for ... Mass. Novopyxis and Cocoon Biotech are each ... --> Cambridge, Mass. Novopyxis ...
(Date:10/13/2015)... 2015 Research and Markets( ) has ... Markets for Bone Morphogenetic Protein Growth Factor Therapy - ... --> --> Bone morphogenetic ... of bone after a fracture. In nature, these proteins ... formation of the skeleton. There are twenty different BMPs ...
(Date:10/13/2015)... and SAN DIEGO , ... Mast Therapeutics, Inc. have agreed to collaborate in the ... poloxamer 188 NF, marketed by BASF under the Kolliphor ... a variety of pharmaceutical and biological applications, such as ... is the starting material for Mast,s lead product candidate. ...
(Date:10/13/2015)... ... October 13, 2015 , ... Exotic Automation & ... solutions and components, is opening its latest Parker Store retail location in Ann, ... Exotic’s second major expansion in Metropolitan Detroit in less than a year. The ...
Breaking Biology Technology:
(Date:9/30/2015)... 30, 2015  The global glucose monitoring device and diabetes ... says a new report on the industry from Kalorama Information. Sales ... the market, followed by continuous glucose monitoring and sensor segment, ... market for these products in its latest report, The ... , ...
(Date:9/28/2015)... NEW YORK , Sept. 28, 2015 ... platform, announced today that its expedited traveler ...  CLEAR,s innovative platform transforms travel, bringing a ... for its members. "CLEAR offers ... which enhances customer service," said Jim ...
(Date:9/28/2015)... , September 28, 2015 ... Component (Hardware & Software), Product (Scanner & Others), Application ... & Defense, & Others) & Geography Global - Forecast ... expected to reach USD 3627.90 Million by 2020, at ... Browse 65 market data T ables ...
Breaking Biology News(10 mins):